SynthesisAntimicrobial resistance and infection control2018
Risk factors for hospitalized patients with resistant or multidrug-resistant
Synthesis in Antimicrobial resistance and infection control, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 9 syntheses or guidelines pooled it, 263 citations in OpenAlex.
- Risk factors for colonisation and infection with multidrug-resistant Pseudomonas aeruginosa in intensive care unit: a systematic review and meta-analysis.Systematic reviews · 2026Pooled it
- Worldwide threatening prevalence of carbapenem-resistantEpidemiology and infection · 2025Pooled it
- Pooled it
- Novel β-lactam antibiotics versus other antibiotics for treatment of complicated urinary tract infections: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Pooled it
- A systematic literature review and expert consensus on risk factors associated to infection progression in adult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteria.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Pooled it
- [A systematic review and expert's analysis of risk factors of infections in adults due to carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii in Spain].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021Pooled it
- Systematic Review and Meta-Analysis of the Occurrence of ESKAPE Bacteria Group in Dogs, and the Related Zoonotic Risk in Animal-Assisted Therapy, and in Animal-Assisted Activity in the Health Context.International journal of environmental research and public health · 2020Pooled it
- Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- A practical nomogram for predicting multidrug-resistant organism infection in a tertiary county-level hospital to guide antimicrobial therapy.New microbes and new infections · 2026Article
- When might we consider using the newer β-lactam agents as empirical therapy against presumed carbapenem-resistant gram-negative infections?JAC-antimicrobial resistance · 2026Review
- Challenges in Antimicrobial Treatment and Antimicrobial Stewardship in Hospital-Acquired Infections in Adult Burn Patients.European burn journal · 2026Review
- Recalibration and Validation of a Risk Scoring Tool to Predict Multidrug-ResistantOpen forum infectious diseases · 2026Article
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Surveillance of temporal trends and antimicrobial resistance in nosocomial respiratory pathogens, Switzerland, 2007 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- ICU-acquired infection in neutropenic patients.Critical care (London, England) · 2026Article
- Synergistic effects of meropenem, amikacin, and ciprofloxacin against carbapenem resistant Pseudomonas aeruginosa isolates.Scientific reports · 2026Article
- Harnessing silica-coated silver nanoparticles for combating multidrug-resistant Pseudomonas aeruginosa.Applied microbiology and biotechnology · 2026Article
- Clinical Distribution and Antimicrobial Resistance Characteristics ofInfection and drug resistance · 2026Article
- The oral-gut-joint axis in osteoarthritis: a multiomics case-control study.Frontiers in cellular and infection microbiology · 2026Observational
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Identifying risk factors predicting acquisition of resistant Methods: MEDLINE®, EMBASE®, and Cochrane Central were searched between 2000 and 2016 for studies examining independent risk factors associated with acquisition of resistant Results: Of the 54 eligible articles, 28 publications (31studies) examined multi-drug resistant (MDR) or extensively drug resistant (XDR) Conclusions: Prior use of antibiotics and prior hospital or ICU stay was the most significant risk factors for acquisition of resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.